Pathway-focused metabolite ratio-based analysis of 49 tumor and 8 normal epithelial cell lines grown in their respective ...

Researchers uncover how 12-hour biological rhythms operate in mammals, exploring their unique mechanisms and potential ...

This phase II study demonstrated the efficacy of osimertinib 80 ... For pharmacokinetic analysis, we collected plasma (2 mL) and CSF (0.3 mL) samples pre-dose on the first day of cycle three and six, ...

DeLLphi-300 (ClinicalTrials.gov identifier: NCT03319940) is a phase I, multicountry, open-label, dose-escalation study evaluating tarlatamab monotherapy and combination with antiprogrammed cell death ...